Moreover, the 36-month beta value for INBS is 4.83. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for INBS is 4.29M and currently, short sellers hold a 9.81% of that float. On November 14, 2024, INBS’s average trading volume was 1.75M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
INBS) stock’s latest price update
The stock price of Intelligent Bio Solutions Inc (NASDAQ: INBS) has dropped by -12.37 compared to previous close of 1.94. Despite this, the company has seen a gain of 11.84% in its stock price over the last five trading days. globenewswire.com reported 2024-10-31 that NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a strategic partnership with B2i Digital to launch an investor-focused marketing campaign. B2i Digital will employ advanced digital marketing strategies to raise awareness of INBS’ patented drug screening technology, which offers a fast, non-invasive, and efficient alternative to traditional drug tests.
INBS’s Market Performance
Intelligent Bio Solutions Inc (INBS) has experienced a 11.84% rise in stock performance for the past week, with a 16.44% rise in the past month, and a 58.14% rise in the past quarter. The volatility ratio for the week is 16.89%, and the volatility levels for the past 30 days are at 9.86% for INBS. The simple moving average for the past 20 days is 9.04% for INBS’s stock, with a -30.99% simple moving average for the past 200 days.
INBS Trading at 1.51% from the 50-Day Moving Average
After a stumble in the market that brought INBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.47% of loss for the given period.
Volatility was left at 9.86%, however, over the last 30 days, the volatility rate increased by 16.89%, as shares surge +14.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.77% upper at present.
During the last 5 trading sessions, INBS rose by +11.84%, which changed the moving average for the period of 200-days by -38.85% in comparison to the 20-day moving average, which settled at $1.5590. In addition, Intelligent Bio Solutions Inc saw -58.07% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for INBS
Current profitability levels for the company are sitting at:
- -3.31 for the present operating margin
- 0.38 for the gross margin
The net margin for Intelligent Bio Solutions Inc stands at -3.27. The total capital return value is set at -1.75. Equity return is now at value -279.27, with -102.00 for asset returns.
Based on Intelligent Bio Solutions Inc (INBS), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -13.18. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -98.41.
Currently, EBITDA for the company is -8.81 million with net debt to EBITDA at 0.32. When we switch over and look at the enterprise to sales, we see a ratio of 1.34. The receivables turnover for the company is 5.51for trailing twelve months and the total asset turnover is 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.12.
Conclusion
To wrap up, the performance of Intelligent Bio Solutions Inc (INBS) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
